Ironwood Pharmaceuticals (IRWD) Assets Average (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $415.7 million for Q1 2026.

• Assets Average for Q1 2026 came in at $415.7 million, up 22.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $415.7 million (up 22.61% YoY), and the FY2025 annual result was $373.9 million, down 9.02% from the prior year.
• Assets Average came in at $415.7 million for Q1 2026 at Ironwood Pharmaceuticals, up from $396.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2023 to a low of $335.1 million in Q2 2025.
• The 5-year median for Assets Average is $454.9 million (2024), against an average of $633.7 million.
• Across the five-year window, Assets Average soared 90.78% in 2022 and sank 59.66% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Assets Average stood at $1.1 billion in 2022, then slumped by 53.52% to $497.6 million in 2023, then slipped by 25.6% to $370.2 million in 2024, then climbed by 7.1% to $396.5 million in 2025, then grew by 4.86% to $415.7 million in 2026.
• The last three Assets Average figures came in at $415.7 million (Q1 2026), $396.5 million (Q4 2025), and $369.5 million (Q3 2025), per Business Quant data.